Vericel/$VCEL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Vericel
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Ticker
$VCEL
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
357
ISIN
US92346J1088
Website
Vericel Metrics
BasicAdvanced
$1.8B
697.66
$0.05
1.33
-
Price and volume
Market cap
$1.8B
Beta
1.33
52-week high
$63.00
52-week low
$35.96
Average daily volume
479K
Financial strength
Current ratio
5.01
Quick ratio
4.203
Long term debt to equity
29.907
Total debt to equity
33.532
Interest coverage (TTM)
-4.57%
Profitability
EBITDA (TTM)
4.003
Gross margin (TTM)
72.54%
Net profit margin (TTM)
1.25%
Operating margin (TTM)
-1.18%
Effective tax rate (TTM)
4.73%
Revenue per employee (TTM)
$670,000
Management effectiveness
Return on assets (TTM)
-0.45%
Return on equity (TTM)
1.13%
Valuation
Price to earnings (TTM)
697.657
Price to revenue (TTM)
7.492
Price to book
6.17
Price to tangible book (TTM)
6.3
Price to free cash flow (TTM)
-270.464
Free cash flow yield (TTM)
-0.37%
Free cash flow per share (TTM)
-13.41%
Growth
Revenue change (TTM)
14.80%
Earnings per share change (TTM)
521.85%
3-year revenue growth (CAGR)
14.79%
10-year revenue growth (CAGR)
19.66%
3-year earnings per share growth (CAGR)
-40.05%
10-year earnings per share growth (CAGR)
-28.78%
What the Analysts think about Vericel
Analyst ratings (Buy, Hold, Sell) for Vericel stock.
Bulls say / Bears say
Vericel reported a 15% year-over-year increase in Q2 2024 revenue, reaching $52.7 million, with MACI revenue growing by 21% to $44.1 million, indicating strong product demand. (stocktitan.net)
The company raised its full-year profitability guidance to a 71% gross margin and a 21% adjusted EBITDA margin, reflecting confidence in sustained financial performance. (stocktitan.net)
Analysts have set an average price target of $63.14 for Vericel, suggesting potential upside from current trading levels. (techdows.com)
StockNews.com downgraded Vericel to a 'Sell' rating, indicating potential concerns about the company's future performance. (etfdailynews.com)
Insider selling activity, including CEO Dominick Colangelo's sale of 17,500 shares, may signal a lack of confidence among executives. (mayfieldrecorder.com)
The stock has experienced a 20% share price drop, leading some analysts to shift their rating from 'Sell' to 'Neutral,' reflecting potential volatility. (stockinvest.us)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
Vericel Financial Performance
Revenues and expenses
Vericel Earnings Performance
Company profitability
Vericel News
AllArticlesVideos
Vericel to Report Second-Quarter 2025 Financial Results on July 31, 2025
GlobeNewsWire·1 day ago
Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025
GlobeNewsWire·1 month ago
Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Vericel stock?
Vericel (VCEL) has a market cap of $1.8B as of July 18, 2025.
What is the P/E ratio for Vericel stock?
The price to earnings (P/E) ratio for Vericel (VCEL) stock is 697.66 as of July 18, 2025.
Does Vericel stock pay dividends?
No, Vericel (VCEL) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Vericel dividend payment date?
Vericel (VCEL) stock does not pay dividends to its shareholders.
What is the beta indicator for Vericel?
Vericel (VCEL) has a beta rating of 1.33. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.